These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35051189)

  • 1. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
    Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
    Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
    Schwarze-Zander C; Piduhn H; Boesecke C; Schlabe S; Stoffel-Wagner B; Wasmuth JC; Strassburg CP; Rockstroh JK
    HIV Med; 2020 Jul; 21(6):378-385. PubMed ID: 32065713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B.
    Cao F; Fan T; Jiang X; Wang J; Liu Y; Zhu L; Xiong Y; Zhang S; Zhang Z; Pan Y; Li Y; Jiang C; Xia J; Yan X; Li J; Liu X; Zhu C; Huang R; Wu C
    Virol J; 2024 Sep; 21(1):234. PubMed ID: 39342240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B.
    Shin H; Lim GS; Yoon JW; Ko Y; Park Y; Park J; Hur MH; Park MK; Cho Y; Lee YB; Cho EJ; Kim BH; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Med Virol; 2024 Jul; 96(7):e29760. PubMed ID: 38940453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.
    Squillace N; Ricci E; Menzaghi B; De Socio GV; Passerini S; Martinelli C; Mameli MS; Maggi P; Falasca K; Cordier L; Celesia BM; Salomoni E; Di Biagio A; Pellicanò GF; Bonfanti P;
    Drug Des Devel Ther; 2020; 14():5515-5520. PubMed ID: 33364747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
    Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
    Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
    Hwang EG; Jung EA; Yoo JJ; Kim SG; Kim YS
    Hepatol Int; 2023 Aug; 17(4):860-869. PubMed ID: 37099248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
    Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
    BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
    Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH
    Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
    Kauppinen KJ; Aho I; Sutinen J
    AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
    Tong K; Chen M; Wang D; Dai H; Peng J; Zhang J; Zhou J; Chang Y; Huang W
    Eur J Clin Pharmacol; 2024 Mar; 80(3):335-354. PubMed ID: 38197944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.